Zero-Knowledge Economy
Discover a carefully curated selection of companies at the forefront of privacy-preserving cryptography. These stocks have been handpicked by our expert analysts for their potential to transform how data is used securely in the digital economy, without ever compromising confidentiality.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
ARQIT QUANTUM INC
ARQQ
Current price
$29.98
This company supplies advanced encryption software services designed to secure data against both current and future threats, including quantum attacks...
This company supplies advanced encryption software services designed to secure data against both current and future threats, including quantum attacks.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
The future of data belongs to those who can use it while protecting it. These companies are commercializing breakthrough cryptographic technologies like zero-knowledge proofs and homomorphic encryption that allow computation on sensitive data without ever exposing it, creating entirely new business models and market opportunities.
What You Need to Know
This theme represents a high-growth, technology-forward investment in the future of secure computation. As AI requires more sensitive data and privacy regulations tighten globally, these firms are positioned to provide the essential infrastructure for tomorrow's digital economy where privacy is paramount.
Why These Stocks
We've selected both pure-play innovators developing privacy-preserving cryptography and established technology leaders implementing these methods at scale. This balanced approach targets companies with defensible market positions in a rapidly expanding field where data security and privacy are becoming mission-critical.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+2.48%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 2.48% over the next year.
Stocks Rated Buy by Analysts
12 of 13 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
The Privacy Revolution
As data breaches make headlines and regulations tighten, companies that can secure data while still making it useful are uniquely positioned to dominate the next wave of tech growth.
AI's Secret Enablers
AI needs massive datasets to improve, but much of the world's most valuable data is confidential. These companies are solving this trillion-dollar problem with technology that unlocks data value without exposure.
Hidden Tech Gems
While everyone watches the big tech names, these specialized security innovators are quietly building the essential infrastructure for tomorrow's data economy, potentially delivering outsized returns.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.